 | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
| Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
Insider Trading - NovoCure Ltd (NVCR)
| | "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2019-11-11 Sale | 2019-11-13 4:33 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $79.57 | $397,850 | 74,504 (Direct) | View |
| 2019-11-11 Sale | 2019-11-13 4:31 pm | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 43,000 | $80.59 | $3,465,392 | 822,683 (Direct) | View |
| 2019-11-11 Sale | 2019-11-13 4:30 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 48,600 | $80.16 | $3,895,925 | 107,179 (Direct) | View |
| 2019-11-04 Sale | 2019-11-06 4:27 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 80,819 | $79 | $6,384,701 | 222,631 (Direct) | View |
| 2019-10-10 Sale | 2019-10-15 4:12 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $72.28 | $361,400 | 74,504 (Direct) | View |
| 2019-09-24 Sale | 2019-09-26 7:52 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 7,992 | $80.63 | $644,398 | 91,210 (Direct) | View |
| 2019-09-13 Sale | 2019-09-17 4:37 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 50,000 | $79.38 | $3,968,881 | 119,663 (Direct) | View |
| 2019-09-11 Sale | 2019-09-13 4:16 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 50,000 | $78.78 | $3,938,842 | 169,663 (Direct) | View |
| 2019-09-10 Sale | 2019-09-12 4:04 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $76.63 | $383,150 | 74,504 (Direct) | View |
| 2019-09-09 Sale | 2019-09-11 4:11 pm | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 50,000 | $78.19 | $3,909,382 | 219,663 (Direct) | View |
| 2019-09-03 Sale | 2019-09-05 4:09 pm | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 158,440 | $87.87 | $13,922,589 | 113,420 (Direct) | View |
| 2019-08-29 Sale | 2019-09-03 4:24 pm | NovoCure Ltd | NVCR | Danziger Asaf CEO | 124,181 | $91.13 | $11,316,198 | 200,869 (Direct) | View |
| 2019-08-30 Sale | 2019-09-03 4:22 pm | NovoCure Ltd | NVCR | PHILLIPS CHARLES G III Director | 22,000 | $91.14 | $2,005,118 | 40,607 (Direct) | View |
| 2019-08-29 Sale | 2019-09-03 4:20 pm | NovoCure Ltd | NVCR | VERNON W ANTHONY Director | 100,000 | $91.03 | $9,103,100 | 158,589 (Direct) | View |
| 2019-08-12 Sale | 2019-08-14 4:18 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $86.45 | $432,250 | 74,504 (Direct) | View |
| 2019-08-02 Sale | 2019-08-06 4:43 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,813 | $85.23 | $154,522 | 76,976 (Direct) | View |
| 2019-07-31 Sale | 2019-08-02 4:13 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 7,020 | $83 | $582,638 | 82,091 (Direct) | View |
| 2019-07-26 Sale | 2019-07-30 3:57 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $77.94 | $974,208 | 89,476 (Direct) | View |
| 2019-07-18 Sale | 2019-07-22 10:47 am | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 7,500 | $70 | $525,000 | 84,476 (Direct) | View |
| 2019-07-10 Sale | 2019-07-12 4:04 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $64.83 | $324,155 | 74,504 (Direct) | View |
| 2019-06-28 Sale | 2019-07-02 4:12 pm | NovoCure Ltd | NVCR | Danziger Asaf CEO | 187,500 | $62.15 | $11,653,125 | 445,811 (Direct) | View |
| 2019-06-27 Sale | 2019-06-28 6:55 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 11,175 | $60.3 | $673,852 | 65,037 (Direct) | View |
| 2019-06-19 Sale | 2019-06-21 4:06 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $60 | $750,000 | 88,712 (Direct) | View |
| 2019-06-19 Sale | 2019-06-21 4:05 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 25,000 | $60.02 | $1,500,500 | 94,504 (Direct) | View |
| 2019-06-19 Sale | 2019-06-21 4:03 pm | NovoCure Ltd | NVCR | Danziger Asaf CEO | 25,000 | $61.46 | $1,536,500 | 283,311 (Direct) | View |
| 2019-06-19 Sale | 2019-06-21 4:01 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 110,868 | $60 | $6,652,080 | 296,542 (Direct) | View |
| 2019-06-18 Sale | 2019-06-19 4:16 pm | NovoCure Ltd | NVCR | Danziger Asaf CEO | 190,338 | $59.37 | $11,300,367 | 448,649 (Direct) | View |
| 2019-06-11 Sale | 2019-06-13 4:16 pm | NovoCure Ltd | NVCR | Danziger Asaf CEO | 47,271 | $55.16 | $2,607,615 | 288,747 (Direct) | View |
| 2019-06-10 Sale | 2019-06-12 4:13 pm | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 1,130 | $55.05 | $62,212 | 76,272 (Direct) | View |
| 2019-06-10 Sale | 2019-06-12 4:12 pm | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $55.05 | $275,266 | 74,504 (Direct) | View |
| 2019-06-06 Sale | 2019-06-10 4:13 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 5,999 | $54.79 | $328,661 | 191,673 (Direct) | View |
| 2019-06-05 Sale | 2019-06-06 4:10 pm | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 17,500 | $54.14 | $947,485 | 203,174 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2019-11-11 Exercise | 2019-11-13 4:33 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:33 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,900 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 4,800 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,900 | $7.03 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 10,000 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 20,000 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 10,000 | $7.03 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,900 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 4,800 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2023-02-19 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,900 | $7.03 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 10,000 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 20,000 | $3.44 | 107,179 (Direct) | View |
| 2019-11-11 Exercise | 2019-11-13 4:30 pm | N/A 2023-02-19 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 10,000 | $7.03 | 107,179 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 10,069 | $14.37 | 222,631 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 36,957 | $22 | 222,631 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 33,793 | $21.15 | 222,631 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A 2025-02-23 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 10,069 | $14.37 | 222,631 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A 2025-10-01 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 36,957 | $22 | 222,631 (Direct) | View |
| 2019-11-04 Exercise | 2019-11-06 4:27 pm | N/A 2028-02-26 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 33,793 | $21.15 | 222,631 (Direct) | View |
| 2019-10-24 Exercise | 2019-10-28 4:28 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 4,580 | $7.48 | 67,721 (Direct) | View |
| 2019-10-24 Exercise | 2019-10-28 4:28 pm | N/A 2024-02-25 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 4,580 | $7.48 | 67,721 (Direct) | View |
| 2019-10-10 Exercise | 2019-10-15 4:12 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-10-10 Exercise | 2019-10-15 4:12 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 2,000 | $3.44 | 91,210 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 4,031 | $3.44 | 91,210 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,961 | $7.03 | 91,210 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 2,000 | $3.44 | 91,210 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 4,031 | $3.44 | 91,210 (Direct) | View |
| 2019-09-24 Exercise | 2019-09-26 7:52 pm | N/A 2023-02-19 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 1,961 | $7.03 | 91,210 (Direct) | View |
| 2019-09-13 Exercise | 2019-09-17 4:37 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 119,663 (Direct) | View |
| 2019-09-13 Exercise | 2019-09-17 4:37 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 119,663 (Direct) | View |
| 2019-09-13 Exercise | 2019-09-17 4:37 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 119,663 (Direct) | View |
| 2019-09-13 Exercise | 2019-09-17 4:37 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 119,663 (Direct) | View |
| 2019-09-11 Exercise | 2019-09-13 4:16 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 169,663 (Direct) | View |
| 2019-09-11 Exercise | 2019-09-13 4:16 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 169,663 (Direct) | View |
| 2019-09-11 Exercise | 2019-09-13 4:16 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 169,663 (Direct) | View |
| 2019-09-11 Exercise | 2019-09-13 4:16 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 169,663 (Direct) | View |
| 2019-09-10 Exercise | 2019-09-12 4:04 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-09-10 Exercise | 2019-09-12 4:04 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-09-09 Exercise | 2019-09-11 4:11 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 219,663 (Direct) | View |
| 2019-09-09 Exercise | 2019-09-11 4:11 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 219,663 (Direct) | View |
| 2019-09-09 Exercise | 2019-09-11 4:11 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 219,663 (Direct) | View |
| 2019-09-09 Exercise | 2019-09-11 4:11 pm | N/A 2021-12-13 | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 25,000 | $3.44 | 219,663 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 59,520 | $6.72 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 11,632 | $6.72 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 56,874 | $7.15 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 30,414 | $21.15 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A 2022-04-29 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 59,520 | $6.72 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A 2022-04-29 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 11,632 | $6.72 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 56,874 | $7.15 | 113,420 (Direct) | View |
| 2019-09-03 Exercise | 2019-09-05 4:09 pm | N/A 2028-02-26 | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 30,414 | $21.15 | 113,420 (Direct) | View |
| 2019-08-30 Exercise | 2019-09-03 4:22 pm | N/A N/A | NovoCure Ltd | NVCR | PHILLIPS CHARLES G III Director | 22,000 | $6.72 | 40,607 (Direct) | View |
| 2019-08-30 Exercise | 2019-09-03 4:22 pm | N/A 2022-09-28 | NovoCure Ltd | NVCR | PHILLIPS CHARLES G III Director | 22,000 | $6.72 | 40,607 (Direct) | View |
| 2019-08-22 Other | 2019-08-26 4:39 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 13,835 | $97.8 | 63,141 (Direct) | View |
| 2019-08-12 Exercise | 2019-08-14 4:18 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-08-12 Exercise | 2019-08-14 4:18 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-07-31 Exercise | 2019-08-02 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 5,115 | $34 | 82,091 (Direct) | View |
| 2019-07-31 Exercise | 2019-08-02 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,718 | $83.3 | 82,091 (Direct) | View |
| 2019-07-31 Exercise | 2019-08-02 4:13 pm | N/A 2028-07-30 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 5,115 | $34 | 82,091 (Direct) | View |
| 2019-07-31 Exercise | 2019-08-02 4:13 pm | 2019-07-31 N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 3,718 | $0 | 82,091 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:12 pm | N/A N/A | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 6,002 | $0 | 852,465 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:12 pm | N/A 2029-07-30 | NovoCure Ltd | NVCR | DOYLE WILLIAM F Chairman | 10,412 | $83.3 | 852,465 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:10 pm | N/A N/A | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 3,001 | $0 | 15,617 (Direct) | View |
| 2019-07-30 Option Award | 2019-08-01 4:10 pm | N/A 2029-07-30 | NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer | 5,206 | $83.3 | 15,617 (Direct) | View |
| 2019-07-26 Exercise | 2019-07-30 3:57 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $19.25 | 89,476 (Direct) | View |
| 2019-07-26 Exercise | 2019-07-30 3:57 pm | N/A 2027-07-25 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $19.25 | 89,476 (Direct) | View |
| 2019-07-18 Exercise | 2019-07-22 10:47 am | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 7,500 | $27.6 | 84,476 (Direct) | View |
| 2019-07-18 Exercise | 2019-07-22 10:47 am | N/A 2028-04-30 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 7,500 | $27.6 | 84,476 (Direct) | View |
| 2019-07-10 Exercise | 2019-07-12 4:04 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-07-10 Exercise | 2019-07-12 4:04 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-07-05 Option Award | 2019-07-09 4:26 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 764 | $27.81 | 76,976 (Direct) | View |
| 2019-07-05 Option Award | 2019-07-09 4:25 pm | N/A N/A | NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel | 696 | $27.81 | 53,900 (Direct) | View |
| 2019-07-05 Option Award | 2019-07-09 4:23 pm | N/A N/A | NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM CFO | 454 | $27.81 | 87,179 (Direct) | View |
| 2019-07-05 Option Award | 2019-07-09 4:22 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 471 | $27.81 | 258,782 (Direct) | View |
| 2019-06-28 Exercise | 2019-07-02 4:12 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 187,500 | $7.15 | 445,811 (Direct) | View |
| 2019-06-28 Exercise | 2019-07-02 4:12 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 187,500 | $7.15 | 445,811 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:06 pm | N/A N/A | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $11.85 | 88,712 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:06 pm | N/A 2027-05-02 | NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer | 12,500 | $11.85 | 88,712 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:05 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 25,000 | $3.44 | 94,504 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:05 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 25,000 | $3.44 | 94,504 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:03 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 25,000 | $11.46 | 283,311 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:03 pm | N/A 2026-02-24 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 25,000 | $11.46 | 283,311 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:01 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 110,868 | $22 | 296,542 (Direct) | View |
| 2019-06-19 Exercise | 2019-06-21 4:01 pm | N/A 2025-10-01 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 110,868 | $22 | 296,542 (Direct) | View |
| 2019-06-18 Exercise | 2019-06-19 4:16 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 190,338 | $14.37 | 448,649 (Direct) | View |
| 2019-06-18 Exercise | 2019-06-19 4:16 pm | N/A 2025-02-23 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 190,338 | $14.37 | 448,649 (Direct) | View |
| 2019-06-11 Exercise | 2019-06-13 4:16 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 16,835 | $14.37 | 288,747 (Direct) | View |
| 2019-06-11 Exercise | 2019-06-13 4:16 pm | N/A N/A | NovoCure Ltd | NVCR | Danziger Asaf CEO | 30,436 | $14.37 | 288,747 (Direct) | View |
| 2019-06-11 Exercise | 2019-06-13 4:16 pm | N/A 2025-02-23 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 16,835 | $14.37 | 288,747 (Direct) | View |
| 2019-06-11 Exercise | 2019-06-13 4:16 pm | N/A 2025-02-23 | NovoCure Ltd | NVCR | Danziger Asaf CEO | 30,436 | $14.37 | 288,747 (Direct) | View |
| 2019-06-10 Exercise | 2019-06-12 4:12 pm | N/A N/A | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-06-10 Exercise | 2019-06-12 4:12 pm | N/A 2021-09-14 | NovoCure Ltd | NVCR | LEUNG GABRIEL Director | 5,000 | $3.44 | 74,504 (Direct) | View |
| 2019-06-06 Exercise | 2019-06-10 4:13 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 5,999 | $7.15 | 191,673 (Direct) | View |
| 2019-06-06 Exercise | 2019-06-10 4:13 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 5,999 | $7.15 | 191,673 (Direct) | View |
| 2019-06-05 Exercise | 2019-06-06 4:10 pm | N/A N/A | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 17,500 | $7.15 | 203,174 (Direct) | View |
| 2019-06-05 Exercise | 2019-06-06 4:10 pm | N/A 2027-02-21 | NovoCure Ltd | NVCR | Ambrogi Michael J. COO | 17,500 | $7.15 | 203,174 (Direct) | View |
| © 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 Fri, 15 Nov 2019 00:03:07 -0600 | SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |